FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro

Oncotarget

Volumn 6, Issue 24, 2015, Pages 20215-20230

  Künstlinger, Helen ^a   Fassunke, Jana ^a   Schildhaus, Hans Ulrich ^b   Brors, Benedikt ^c   Heydt, Carina ^a   Ihle, Michaela Angelika ^a   Mechtersheimer, Gunhild ^d   Wardelmann, Eva ^e   Büttner, Reinhard ^a   Merkelbach Bruse, Sabine ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

FGFR inhibition; Fibroblast growth factor; Gene expression; Myxoid liposarcoma; Whole genome microarray

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; COMPLEMENTARY DNA; DOVITINIB; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; INFIGRATINIB; RNA; SMALL INTERFERING RNA; TRABECTEDIN; FGFR2 PROTEIN, HUMAN; PYRIMIDINE DERIVATIVE;

ADIPOSE TISSUE; APOPTOSIS; ARTICLE; CANCER TISSUE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DNA SYNTHESIS; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MICROARRAY ANALYSIS; MLS 1765 CELL LINE; MLS 402 CELL LINE; MYXOSARCOMA; PROTEIN EXPRESSION; QUALITY CONTROL; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; SARCOMA CELL LINE; SIGNAL TRANSDUCTION; TUMOR GROWTH; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL MOTION; COHORT ANALYSIS; DRUG EFFECTS; GENE EXPRESSION; GENETICS; LIPOSARCOMA, MYXOID; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COHORT STUDIES; GENE EXPRESSION; HUMANS; LIPOSARCOMA, MYXOID; MICROARRAY ANALYSIS; PYRIMIDINES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84940189823     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4046     Document Type: Article

References (48)

1. Wibmer C, Leithner A, Zielonke N, Sperl M and Windhager R. Increasing incidence rates of soft tissue sarcomas? A population-based epidemiologic study and literature review. Ann Oncol. 2010; 21:1106-1111.
2. Hameed M. Pathology and genetics of adipocytic tumors. Cytogenet Genome Res. 2007; 118:138-147.
3. Coindre JM, Pedeutour F and Aurias A. Well-differentiated and dedifferentiated liposarcomas. Virchows Arch. 2010; 456:167-179.
4. Muller CR, Paulsen EB, Noordhuis P, Pedeutour F, Saeter G and Myklebost O. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int J Cancer. 2007; 121:199-205.
5. Antonescu CR, Tschernyavsky SJ, Decuseara R, Leung DH, Woodruff JM, Brennan MF, Bridge JA, Neff JR, Goldblum JR and Ladanyi M. Prognostic impact of P53 status, TLSCHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res. 2001; 7:3977-3987.
6. Crozat A, Aman P, Mandahl N and Ron D. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature. 1993; 363:640-644.
7. Panagopoulos I, Hoglund M, Mertens F, Mandahl N, Mitelman F and Aman P. Fusion of the EWS and CHOP genes in myxoid liposarcoma. Oncogene. 1996; 12:489-494.
8. Rabbitts TH, Forster A, Larson R and Nathan P. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nat Genet. 1993; 4:175-180.
9. Antonescu CR, Elahi A, Humphrey M, Lui MY, Healey JH, Brennan MF, Woodruff JM, Jhanwar SC and Ladanyi M. Specificity of TLS-CHOP rearrangement for classic myxoid/round cell liposarcoma: absence in predominantly myxoid well-differentiated liposarcomas. J Mol Diagn. 2000; 2:132-138.
10. Beck AH, West RB and van de Rijn M. Gene expression profiling for the investigation of soft tissue sarcoma pathogenesis and the identification of diagnostic, prognostic, and predictive biomarkers. Virchows Arch. 2010; 456:141-151.
11. Baird K, Davis S, Antonescu CR, Harper UL, Walker RL, Chen Y, Glatfelter AA, Duray PH and Meltzer PS. Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res. 2005; 65:9226-9235.
12. Francis P, Namlos HM, Muller C, Eden P, Fernebro J, Berner JM, Bjerkehagen B, Akerman M, Bendahl PO, Isinger A, Rydholm A, Myklebost O and Nilbert M. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics. 2007; 8:73.
13. Renner M, Wolf T, Meyer H, Hartmann W, Penzel R, Ulrich A, Lehner B, Hovestadt V, Czwan E, Egerer G, Schmitt T, Alldinger I, Renker EK, et al. Integrative DNA methylation and gene expression analysis in high-grade soft tissue sarcomas. Genome Biol. 2013; 14:r137.
14. Singer S, Socci ND, Ambrosini G, Sambol E, Decarolis P, Wu Y, O'Connor R, Maki R, Viale A, Sander C, Schwartz GK and Antonescu CR. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res. 2007; 67:6626-6636.
15. Edris B, Fletcher JA, West RB, van de Rijn M and Beck AH. Comparative gene expression profiling of benign and malignant lesions reveals candidate therapeutic compounds for leiomyosarcoma. Sarcoma. 2012; 2012:805614.
16. Casali PG, Sanfilippo R and D'Incalci M. Trabectedin therapy for sarcomas. Curr Opin Oncol. 2010; 22:342-346.
17. Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, Pasqualini F, Grosso F, Sanfilippo R, Casali PG, Gronchi A, Virdis E, Tarantino E, et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res. 2010; 70:2235-2244.
18. Davis IJ, McFadden AW, Zhang Y, Coxon A, Burgess TL, Wagner AJ and Fisher DE. Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma. Cancer Res. 2010; 70:639-645.
19. Butrynski JE, D'Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC, Ladanyi M, Capelletti M, Rodig SJ, Ramaiya N, Kwak EL, Clark JW, Wilner KD, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med. 2010; 363:1727-1733.
20. Judson I. Targeted therapies in soft tissue sarcomas. Ann Oncol. 2010; 21 Suppl 7:vii277-280.
21. Taylor JGt, Cheuk AT, Tsang PS, Chung JY, Song YK, Desai K, Yu Y, Chen QR, Shah K, Youngblood V, Fang J, Kim SY, Yeung C, et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest. 2009; 119:3395-3407.
22. Fernanda Amary M, Ye H, Berisha F, Khatri B, Forbes G, Lehovsky K, Frezza AM, Behjati S, Tarpey P, Pillay N, Campbell PJ, Tirabosco R, Presneau N, et al. Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy. Cancer medicine. 2014; 3:980-987.
23. Zhang K, Chu K, Wu X, Gao H, Wang J, Yuan YC, Loera S, Ho K, Wang Y, Chow W, Un F, Chu P and Yen Y. Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in high-grade liposarcoma. Cancer Res. 2013; 73:1298-1307.
24. Dheda K, Huggett JF, Chang JS, Kim LU, Bustin SA, Johnson MA, Rook GA and Zumla A. The implications of using an inappropriate reference gene for real-time reverse transcription PCR data normalization. Anal Biochem. 2005; 344:141-143.
25. Fassunke J, Blum MC, Schildhaus HU, Zapatka M, Brors B, Kunstlinger H, Buttner R, Wardelmann E and Merkelbach-Bruse S. qPCR in gastrointestinal stromal tumors: Evaluation of reference genes and expression analysis of KIT and the alternative receptor tyrosine kinases FLT3, CSF1-R, PDGFRB, MET and AXL. BMC Mol Biol. 2010; 11:100.
26. Huggett J, Dheda K, Bustin S and Zumla A. Real-time RTPCR normalisation; strategies and considerations. Genes Immun. 2005; 6:279-284.
27. Bustin SA, Benes V, Nolan T and Pfaffl MW. Quantitative real-time RT-PCR-a perspective. J Mol Endocrinol. 2005; 34:597-601.
28. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004; 101:13306-13311.
29. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, Fletcher JA and Demetri GD. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 2001; 20:5054-5058.
30. Turner N and Grose R. Fibroblast growth factor signaling: from development to cancer. Nat Rev Cancer. 2010; 10:116-129.
31. Di Martino E, Tomlinson DC and Knowles MA. A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges. Adv Urol. 2012; 2012:Article ID 429213.
32. Byron SA, Gartside MG, Wellens CL, Goodfellow PJ, Birrer MJ, Campbell IG and Pollock PM. FGFR2 mutations are rare across histologic subtypes of ovarian cancer. Gynecol Oncol. 2010; 117:125-129.
33. Kunii K, Davis L, Gorenstein J, Hatch H, Yashiro M, Di Bacco A, Elbi C and Lutterbach B. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res. 2008; 68:2340-2348.
34. Pardo OE, Latigo J, Jeffery RE, Nye E, Poulsom R, Spencer-Dene B, Lemoine NR, Stamp GW, Aboagye EO and Seckl MJ. The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo. Cancer Res. 2009; 69:8645-8651.
35. Tomlinson DC, Lamont FR, Shnyder SD and Knowles MA. Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer. Cancer Res. 2009; 69:4613-4620.
36. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, Moch H, Wagener P, Fischer F, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med. 2010; 2:62ra93.
37. Guagnano V, Furet P, Spanka C, Bordas V, Le Douget M, Stamm C, Brueggen J, Jensen MR, Schnell C, Schmid H, Wartmann M, Berghausen J, Drueckes P, et al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethylpiperazin-1-yl)-phenylamin o]-pyrimidin-4-yl}-1-methylurea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem. 2011; 54:7066-7083.
38. Gavine PR, Mooney L, Kilgour E, Thomas AP, Al-Kadhimi K, Beck S, Rooney C, Coleman T, Baker D, Mellor MJ, Brooks AN and Klinowska T. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012; 72:2045-2056.
39. Girnita L, Girnita A, Wang M, Meis-Kindblom JM, Kindblom LG and Larsson O. A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells. Oncogene. 2000; 19:4298-4301.
40. Ishibe T, Nakayama T, Okamoto T, Aoyama T, Nishijo K, Shibata KR, Shima Y, Nagayama S, Katagiri T, Nakamura Y, Nakamura T and Toguchida J. Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy. Clin Cancer Res. 2005; 11:2702-2712.
41. Schweiger N, Hauck M, Steinhoff H, Sampl S, Reifinger M, Walter I, Kreilmeier T, Marian B, Grusch M, Berger W, Holzmann K and Kleiter M. Canine and human sarcomas exhibit predominant FGFR1 expression and impaired viability after inhibition of signaling. Molecular carcinogenesis. 2014:In press.
42. Patel NG, Kumar S and Eggo MC. Essential role of fibroblast growth factor signaling in preadipoctye differentiation. J Clin Endocrinol Metab. 2005; 90:1226-1232.
43. Kilvaer TK, Valkov A, Sorbye SW, Smeland E, Bremnes RM, Busund LT and Donnem T. Fibroblast growth factor 2 orchestrates angiogenic networking in non-GIST STS patients. J Transl Med. 2011; 9:104.
44. Allerstorfer S, Sonvilla G, Fischer H, Spiegl-Kreinecker S, Gauglhofer C, Setinek U, Czech T, Marosi C, Buchroithner J, Pichler J, Silye R, Mohr T, Holzmann K, et al. FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities. Oncogene. 2008; 27:4180-4190.
45. Antoine M, Wirz W, Tag CG, Mavituna M, Emans N, Korff T, Stoldt V, Gressner AM and Kiefer P. Expression pattern of fibroblast growth factors (FGFs), their receptors and antagonists in primary endothelial cells and vascular smooth muscle cells. Growth Factors. 2005; 23:87-95.
46. Edgar R, Domrachev M and Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002; 30:207-210.
47. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A and Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002; 3:RESEARCH0034.
48. Pfaffl MW, Horgan GW and Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002; 30:e36.